Meet the expert
John Petricciani is president of the International Alliance for Biological Standardization (IABS), a non-profit organization devoted to scientific and medical advancement of biologicals. He also serves on the World Health Organization (WHO) Expert Panel on Biologicals, is an adjunct staff member at the John Wayne Cancer Institute, and is an honorary professor of the Institute of Medical Biology at the Chinese Academy of Medical Sciences, China.
Dr. Petricciani currently is licensed to practice medicine in California and Washington, D.C., and has held senior research, medical, and administrative positions in the public and private sectors, including the Pharmaceutical Manufacturers Association and the WHO, where he held a number of positions including chief medical officer.
Dr. Petricciani previously served as the director of the Office of Biologics at the U.S. Food and Drug Administration (FDA).
Dr. Petricciani received a bachelor of science in chemistry from Rensselaer Polytechnic Institute, a master of science in chemistry from the University of Nevada, and a doctorate in medicine (M.D.) from Stanford University. He is a fellow of the Royal Society of Medicine (UK) and has authored or co-authored more than 160 articles on tumor cell assays, cytogenetics, and regulatory policy. Additionally, he is an editorial board member of the journal Biologicals.
with John Petricciani, M.D.
Scientific discoveries of the past decades have increased our understanding of underlying disease pathways and identified potential biological products for diagnosis, treatment, and prevention of certain important diseases.1
As new biological medicines become available around the world, healthcare professionals face an increasing number of choices when selecting an appropriate treatment. Concurrently, issues related to manufacturing, including contamination, counterfeiting, and drug shortages, have occurred and can compromise the health and well-being of patients prescribed these medicines.2-4
For biological medicines, variations in the production process can result in unpredictable changes that profoundly alter their safety and efficacy profile.3,5,6 The knowledge, expertise, resources, and track record of a manufacturer and its ability to ensure product quality and supply should be considered when choosing a biological medicine.
Questions and answers with Dr. Petricciani
Submit a question to Dr. Petricciani
If you have a question not addressed above we invite you to submit your query to Dr. Petricciani.